Showing 2581-2590 of 3873 results for "".
Is Topical Therapy for Psoriasis Resurging?
https://practicaldermatology.com/topics/psoriasis/PD0409_03-php/22841/While biologics have changed the way patients and physicians think about psoriasis, topical therapy remains important for a majority of patients.Recent Developments
https://practicaldermatology.com/columns/recent-developments/PD0409_05-php/22843/What Do New PhRMA Guidelines Mean for Dermatology?
https://practicaldermatology.com/topics/general-topics/PD0309_04-php/22858/Revisions to the "Code on Interactions" are taking effect, but what do they really mean for the typical clinician?Recent Developments
https://practicaldermatology.com/columns/recent-developments/PD0309_06-php/22860/You Want to Start A New Practice: Now What?
https://practicaldermatology.com/topics/general-topics/PD0309_12-php/22866/After making the decision to start a practice, constructing a solid business plan and financial overview is critical.- J&J Seeks FDA Approval for Pediatric Tremfya Indicationshttps://practicaldermatology.com/news/jj-seeks-fda-approval-pediatric-tremfya-indications/2468706/Johnson & Johnson (J&J) has submitted supplemental Biologics License Applications (sBLAs) to the U.S. Food and Drug Administration (FDA) for Tremfya (guselkumab), seeking approval for pediatric indications. Tremfya, the first approved monoclonal antibody IL-23 inhibitor that select
- J&J Expands Atopic Dermatitis Pipeline with Yellow Jersey Therapeutics Acquisitionhttps://practicaldermatology.com/news/jj-expands-ad-pipeline-yellow-jersey-therapeutics-125-billion-acquisition/2463207/Johnson & Johnson (J&J) has announced its plan to acquire Yellow Jersey Therapeutics (a subsidiary of Numab Therapeutics) for $1.25 billion in cash, according to a news release. The acquisition includes the bispecific antibody NM26, which is currently advancing to phase 2 studies f
- Cynosure to Name Stephen J. Webber as New CFOhttps://practicaldermatology.com/news/cynosure-to-name-stephen-j-webber-as-new-cfo/2458436/Cynosure, Inc. announced that Stephen J. Webber will join the company on October 10, 2016 as Executive Vice President. Mr. Webber will then become Chief Financial Officer and Chief Accounting Officer effective upon the filing in Novembe
- ASLMS to Honor David J. Cuccia, PhDhttps://practicaldermatology.com/news/20120314-aslms_to_honor_david_j_cuccia_phd/2459844/David J. Cuccia, Ph.D, Chief Technology Officer and CEO at Modulated Imaging, Inc. Irvine, California, will receive the 2012 Dr. Horace Furumoto Innovations Professional Development Grant at the Annual Conference of the American Society for Laser Medicine and Surgery
- Gryphon Acquires Roc Skincare from J & Jhttps://practicaldermatology.com/news/gryphon-acquires-roc-skincare-from-j-j/2459930/Gryphon Investors has acquired RoC Skincare from Johnson & Johnson Consumer, Inc. The transaction is Gryphon's second investment in the beauty sector after the firm acquired indie color cosmet